We use cookies to help us improve your browsing experience and understand how people use our website. Our privacy statement explains how we use cookies, and how to change your cookie settings.

Toledo program

Toledo program

The Toledo program is a strategic effort to develop assets inhibiting salt-inducible kinases (SIK). Our lead molecule, GLPG3970, inhibits SIK2/SIK3 and effectuates a dual mode of action on inflammation by stimulating anti-inflammatory cytokines and inhibiting pro-inflammatory cytokines. We have observed encouraging activity in various inflammatory preclinical models with compounds targeting this class.

Our R&D Roundtable 2020 on the Toledo Program can be found here.

The development strategy for Toledo is to advance multiple Toledo candidates across different selectivity profiles, and to test these in a broad panel of in vivo disease models targeting a number of indications.

We are now executing on a broad program to discover and develop multiple series of compounds acting on the Toledo class of targets, aimed at activity across numerous conditions, with a key focus on inflammation.

Toledo program - Parallel Proof of Concept studies

In 2019 we initiated a Phase 1 trial with GLPG3970, a compound acting on SIK1/SIK2. We expect to launch multiple proof-of-concept patient trials in the second half of 2020 and expect to report topline data from our first patient study in 2021.

Gilead has an option to in-license the ex-European commercial rights to each of the Toledo molecules following completion of Phase 2 trials.